- 儀器無憂網(wǎng)
- 服務中心
邁瑞
Mindray
邁瑞mindray www.mindray.com.cn 中文網(wǎng)站
邁瑞公司是中國領(lǐng)先的高科技醫(yī)療設(shè)備研發(fā)制造廠商，同時也是全球醫(yī)療設(shè)備的創(chuàng)新領(lǐng)導者之一。 自1991年成立以來，邁瑞公司始終致力于臨床醫(yī)療設(shè)備的研發(fā)和制造，產(chǎn)品涵蓋生命信息與支持、臨床檢驗及試劑、數(shù)字超聲、放射影像四大領(lǐng)域，將性能與價格完美平衡的醫(yī)療電子產(chǎn)品帶到世界每一角落。時至今日，邁瑞公司在全球范圍內(nèi)的銷售已擴展至190多個國家和地區(qū)。
邁瑞公司總部位于中國深圳，同時在深圳、北京、南京、成都、西安、上海、美國西雅圖、新澤西、瑞典斯德哥爾摩設(shè)立有研發(fā)中心，在中國31個主要城市設(shè)立了分公司，在美國、加拿大、英國、荷蘭、德國、法國、意大利、俄羅斯、土耳其、印度、印尼、墨西哥、巴西、西班牙、埃及、哥倫比亞設(shè)立了海外子公司，在世界各地形成強大的分銷和服務網(wǎng)絡(luò)。截至2010年12月，全球員工超過6,300人。
2006年9月邁瑞公司作為中國首家醫(yī)療設(shè)備企業(yè)在美國紐交所成功上市；同年10月，獲科技部批準正式掛牌成立“國家醫(yī)用診斷儀器工程技術(shù)研究中心”。2008年5月完成對美國Datascope監(jiān)護業(yè)務的收購，成為全球生命信息監(jiān)護領(lǐng)域的第三大品牌。擔綱引領(lǐng)民族醫(yī)療設(shè)備發(fā)展之重任，邁瑞公司正朝著成為守護人類健康的核心力量的宏偉愿景跨越發(fā)展。
深圳邁瑞生物醫(yī)療電子股份有限公司（總部）
地址：深圳市南山區(qū)高新技術(shù)產(chǎn)業(yè)園區(qū)科技南十二路邁瑞大廈
電話：(0755) 26582888 傳真：(0755) 26582680
郵編：518057 網(wǎng)址：www.mindray.com
Mindray was founded in 1991 with the goal of delivering high-quality, competitively priced medical devices to make healthcare more accessible and affordable around the world. In 2006, Mindray listed on the New York Stock Exchange and is now a leading developer, manufacturer and marketer of medical devices worldwide.
The company has three well-established business segments: Patient Monitoring and Life Support Products, In-Vitro Diagnostic Products and Medical Imaging Systems. Health care facilities equipped with Mindray’s products can be found in over 190 countries and regions. A sound distribution and service network has been formed with 31 branch offices throughout China, and overseas subsidiaries in Brazil, Canada, France, Germany, India, Indonesia, Italy, Mexico, Netherlands, Russia, Turkey, the UK and the U.S. , Spain, Egypt and Columbia. Additionally, the acquisition of Datascope Corporation's patient monitoring business has added significant direct sales and service capabilities on the ground in the U.S. and Western Europe.
Mindray has a global R&D network with research centers in Shenzhen, Beijing, Nanjing, Seattle, New Jersey and Stockholm. Approximately 10% of total revenue has been consistently re-invested into R&D each year. An average of eight new products has annually been introduced to the market over the past seven years.
